Global private equity and venture capital news and research

Posts Tagged ‘therapeutics’

29 October 2015

Frazier Healthcare closes first dedicated venture fund on $262m

doctor nurse healthcare surgery hospital US investment firm Frazier Healthcare Partners has closed its first sector-specific early-stage fund on $262m.

28 September 2015

Atlas Venture-led consortium helps fund latest Replimune cancer research

lab-217041_1280 Early-stage investment firm Atlas Venture has headed a group of investors to successfully close a $30m financing round for Oxford-based cancer therapeutics firm Replimune.

11 August 2015

Gores Group seals $1.3bn Therakos trade exit three years after buyout

white-blood-cell-543471_1280 Global private equity firm The Gores Group has agreed to sell light-activated drug treatment provider Therakos in a $1.3bn trade sale three years after picking up the business.

7 August 2014

Venture capital-backed Juno Therapeutics raises $134m Series B

cancer juno Venture capital-backed biotechnology startup Juno Therapeutics has raised $134m in its Series B round to fund the development of its immunotherapies for cancer.

22 April 2014

Vivo Capital leads $58.5m Series D for ProNAi Therapeutics

biotech_lrg Nucleic acid therapeutics developer ProNAi Therapeutics has secured $59.5m in a Series D round led by venture capital firm Vivo Capital.

3 January 2014

Venture capital-backed Revance eyes Nasdaq IPO

stock brokerage market share listed Venture capital-backed biopharmaceutical company Revance Therapeutics is looking to raise $86.25m via an IPO on the Nasdaq exchange.

16 October 2013

SAGE Therapeutics raises $20m from Arch Venture Partners, Third Rock

pharmaceutical 12_sq Arch Venture Partners and Third Rock Ventures have invested $20m in SAGE Therapeutics, bringing the biopharmaceutical company’s fundraising total to $57.8m.

5 May 2011

Dutch BioGeneration Ventures raises second fund

Dutch venture capital firm BioGeneration Ventures has held an interim closing on its most recent life sciences BioGeneration Ventures II fund with a target of €30m. The fund has attracted existing and new LPs with backers including the Dutch Ministry of Economic Affairs, Agriculture and Innovation which invested through a TechnoPartner seed facility loan. The[...]

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016